0000899243-19-010278.txt : 20190408
0000899243-19-010278.hdr.sgml : 20190408
20190408194727
ACCESSION NUMBER: 0000899243-19-010278
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190404
FILED AS OF DATE: 20190408
DATE AS OF CHANGE: 20190408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jouhikainen Jaakko Taneli
CENTRAL INDEX KEY: 0001703641
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32157
FILM NUMBER: 19738297
MAIL ADDRESS:
STREET 1: 900 S CAPITAL OF TEXAS HWY, SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Savara Inc
CENTRAL INDEX KEY: 0001160308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841318182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY
STREET 2: SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
BUSINESS PHONE: 512-614-1848
MAIL ADDRESS:
STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY
STREET 2: SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
FORMER COMPANY:
FORMER CONFORMED NAME: Mast Therapeutics, Inc.
DATE OF NAME CHANGE: 20130312
FORMER COMPANY:
FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030613
FORMER COMPANY:
FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-04
0
0001160308
Savara Inc
SVRA
0001703641
Jouhikainen Jaakko Taneli
6836 BEE CAVE ROAD, BUILDING III
SUITE 200
AUSTIN
TX
78746
0
1
0
0
President and COO
Common Stock
2019-04-04
4
S
0
7815
9.00
D
184754
D
Common Stock
2019-04-05
4
S
0
849
9.00
D
183905
D
Common Stock
2019-04-08
4
S
0
16336
9.0407
D
167569
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2018.
The price is a weighted average sale price. The sale prices ranged from $9.00 to $9.17. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
/s/ David Lowrance, David Lowrance as attorney-in-fact for Jaakko Taneli Jouhikainen
2019-04-08